Publications 2009
Ahmed S, Thomas G, Ghoussaini M, Healey CS, Humphreys MK, Platte R, Morrison J, Maranian M, Pooley KA, Luben R, Eccles D, Evans DG, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Stratton MR, Rahman N, Jacobs K, Prentice R, Anderson GL, Rajkovic A, Curb JD, Ziegler RG, Berg CD, Buys SS, McCarty CA, Feigelson HS, Calle EE, Thun MJ, Diver WR, Bojesen S, Nordestgaard BG, Flyger H, Dörk T, Schürmann P, Hillemanns P, Karstens JH, Bogdanova NV, Antonenkova NN, Zalutsky IV, Bermisheva M, Fedorova S, Khusnutdinova E, , Kang D, Yoo KY, Noh DY, Ahn SH, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Garcia-Closas M, Lissowska J, Brinton L, Peplonska B, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Hopper JL, Southey MC, Smith L, Spurdle AB, Schmidt MK, Broeks A, van Hien RR, Cornelissen S, Milne RL, Ribas G, González-Neira A, Benitez J, Schmutzler RK, Burwinkel B, Bartram CR, Meindl A, Brauch H, Justenhoven C, Hamann U, , Chang-Claude J, Hein R, Wang-Gohrke S, Lindblom A, Margolin S, Mannermaa A, Kosma VM, Kataja V, Olson JE, Wang X, Fredericksen Z, Giles GG, Severi G, Baglietto L, English DR, Hankinson SE, Cox DG, Kraft P, Vatten LJ, Hveem K, Kumle M, Sigurdson A, Doody M, Bhatti P, Alexander BH, Hooning MJ, van den Ouweland AM, Oldenburg RA, Schutte M, Hall P, Czene K, Liu J, Li Y, Cox A, Elliott G, Brock I, Reed MW, Shen CY, Yu JC, Hsu GC, Chen ST, Anton-Culver H, Ziogas A, Andrulis IL, Knight JA, , , Beesley J, Goode EL, Couch F, Chenevix-Trench G, Hoover RN, Ponder BA, Hunter DJ, Pharoah PD, Dunning AM, Chanock SJ, Easton DF
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.
Nat Genet. 2009 May;41(5):585-90
Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ
Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
PLoS One. 2009;4(3):e4710
Armstrong AJ, Halabi S, de Wit R, Tannock IF, Eisenberger M
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
Prostate Cancer Prostatic Dis. 2009;12(1):88-93
Baird RD, Kitzen J, Clarke PA, Planting A, Reade S, Reid A, Welsh L, López Lázaro L, de las Heras B, Judson IR, Kaye SB, Eskens F, Workman P, deBono JS, Verweij J
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors.
Mol Cancer Ther. 2009 Jun;8(6):1430-7
Benjamin RS, Debiec-Rychter M, Le Cesne A, Sleijfer S, Demetri GD, Joensuu H, Schöffski P, Poveda A
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment.
Semin Oncol. 2009 Aug;36(4):302-11
Bobisse S, Rondina M, Merlo A, Tisato V, Mandruzzato S, Amendola M, Naldini L, Willemsen RA, Debets R, Zanovello P, Rosato A
Reprogramming T lymphocytes for melanoma adoptive immunotherapy by T-cell receptor gene transfer with lentiviral vectors.
Cancer Res. 2009 Dec 15;69(24):9385-94
Bogaerts J, Ford R, Sargent D, Schwartz LH, Rubinstein L, Lacombe D, Eisenhauer E, Verweij J, Therasse P,
Individual patient data analysis to assess modifications to the RECIST criteria.
Eur J Cancer. 2009 Jan;45(2):248-60
Boonstra JJ, Koppert LB, Wijnhoven BP, Tilanus HW, Van Dekken H, Tran TC, Van der Gaast A
Chemotherapy followed by surgery in patients with carcinoma of the distal esophagus and celiac lymph node involvement.
J Surg Oncol. 2009 Oct 1;100(5):407-13
Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massagué J
Genes that mediate breast cancer metastasis to the brain.
Nature. 2009 Jun 18;459(7249):1005-9
Bottomley A, Coens C, Suciu S, Santinami M, Kruit W, Testori A, Marsden J, Punt C, Salès F, Gore M, Mackie R, Kusic Z, Dummer R, Patel P, Schadendorf D, Spatz A, Keilholz U, Eggermont A
Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
J Clin Oncol. 2009 Jun 20;27(18):2916-23
Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM,
Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.
J Natl Cancer Inst. 2009 Jun 16;101(12):869-77
Brooimans RA, Kraan J, van Putten W, Cornelissen JJ, Löwenberg B, Gratama JW
Flow cytometric differential of leukocyte populations in normal bone marrow: Influence of peripheral blood contamination1.
Cytometry B Clin Cytom. 2008 Oct 21;76B(1):18-26
Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY,
Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 2009 May;20 Suppl 4:132-6
Creighton CJ, Kent Osborne C, van de Vijver MJ, Foekens JA, Klijn JG, Horlings HM, Nuyten D, Wang Y, Zhang Y, Chamness GC, Hilsenbeck SG, Lee AV, Schiff R
Molecular profiles of progesterone receptor loss in human breast tumors.
Breast Cancer Res Treat. 2009 Mar;114(2):287-99
de Beukelaar JW, Milikan JC, Verjans GM, de Graaf MT, van Norden Y, Lamers CH, van den Bent MJ, Bromberg JE, Hulsenboom E, Sintnicolaas K, Gratama JW, Sillevis Smitt PA
No evidence for the presence of HuD-specific T cells in the cerebrospinal fluid of patients with Hu-associated paraneoplastic neurological syndromes.
J Neurol. 2009 Feb;256(2):279-82
de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC
Micrometastases or isolated tumor cells and the outcome of breast cancer.
N Engl J Med. 2009 Aug 13;361(7):653-63
de Bruijn P, Moghaddam-Helmantel IM, de Jonge MJ, Meyer T, Lam MH, Verweij J, Wiemer EA, Loos WJ
Validated bioanalytical method for the quantification of RGB-286638, a novel multi-targeted protein kinase inhibitor, in human plasma and urine by liquid chromatography/tandem triple-quadrupole mass spectrometry.
J Pharm Biomed Anal. 2009 Dec 5;50(5):977-82
Deprimo SE, Huang X, Blackstein ME, Garrett CR, Harmon CS, Schöffski P, Shah MH, Verweij J, Baum CM, Demetri GD
Circulating levels of soluble KIT serve as a biomarker for clinical outcome in gastrointestinal stromal tumor patients receiving sunitinib following imatinib failure.
Clin Cancer Res. 2009 Sep 15;15(18):5869-77
De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P, Skoneczna I, Marreaud S, de Wit R, Sylvester R
Randomized phase II/III trial assessing gemcitabine/ carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II--results of EORTC study 30986.
J Clin Oncol. 2009 Nov 20;27(33):5634-9
Dols LF, Verhoef C, Eskens FA, Schouten O, Nonner J, Hop WC, Méndez Romero A, de Man RA, van der Linden E, Dwarkasing RS, IJzermans JN
[Improvement of 5 year survival rate after liver resection for colorectal metastases between 1984-2006]
Ned Tijdschr Geneeskd. 2009 Mar 14;153(11):490-5
Duffy MJ, Napieralski R, Martens JW, Span PN, Spyratos F, Sweep FC, Brunner N, Foekens JA, Schmitt M,
Methylated genes as new cancer biomarkers.
Eur J Cancer. 2009 Feb;45(3):335-46
Dykgraaf RH, de Jong D, van Veen M, Ewing-Graham PC, Helmerhorst TJ, van der Burg ME
Clinical management of ovarian small-cell carcinoma of the hypercalcemic type: a proposal for conservative surgery in an advanced stage of disease.
Int J Gynecol Cancer. 2009 Apr;19(3):348-53
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
Eur J Cancer. 2009 Jan;45(2):228-47
Eskens FA, Steeghs N, Verweij J, Bloem JL, Christensen O, van Doorn L, Ouwerkerk J, de Jonge MJ, Nortier JW, Kraetzschmar J, Rajagopalan P, Gelderblom H
Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
J Clin Oncol. 2009 Sep 1;27(25):4169-76
Fekkes D, Van Gool AR, Bannink M, Sleijfer S, Kruit WH, van der Holt B, Eggermont AM, Hengeveld MW, Stoter G
Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-alpha therapy.
Amino Acids. 2009 Oct;37(4):703-8
Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity.
Clin Pharmacol Ther. 2009 Oct;86(4):396-402
Ford R, Schwartz L, Dancey J, Dodd LE, Eisenhauer EA, Gwyther S, Rubinstein L, Sargent D, Shankar L, Therasse P, Verweij J
Lessons learned from independent central review.
Eur J Cancer. 2009 Jan;45(2):268-74
Fusi A, Collette S, Busse A, Suciu S, Rietz A, Santinami M, Kruit WH, Testori A, Punt CJ, Dalgleish AG, Spatz A, Eggermont AM, Keilholz U
Circulating melanoma cells and distant metastasis-free survival in stage III melanoma patients with or without adjuvant interferon treatment (EORTC 18991 side study).
Eur J Cancer. 2009 Dec;45(18):3189-97
Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA, Rimm DL, Laird PW, Garcia-Closas M, Sherman ME
DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations.
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):3036-43
Gaudet MM, Milne RL, Cox A, Camp NJ, Goode EL, Humphreys MK, Dunning AM, Morrison J, Giles GG, Severi G, Baglietto L, English DR, Couch FJ, Olson JE, Wang X, Chang-Claude J, Flesch-Janys D, Abbas S, Salazar R, Mannermaa A, Kataja V, Kosma VM, Lindblom A, Margolin S, Heikkinen T, Kämpjärvi K, Aaltonen K, Nevanlinna H, Bogdanova N, Coinac I, Schürmann P, Dörk T, Bartram CR, Schmutzler RK, Tchatchou S, Burwinkel B, Brauch H, Torres D, Hamann U, Justenhoven C, Ribas G, Arias JI, Benitez J, Bojesen SE, Nordestgaard BG, Flyger HL, Peto J, Fletcher O, Johnson N, Dos Santos Silva I, Fasching PA, Beckmann MW, Strick R, Ekici AB, Broeks A, Schmidt MK, van Leeuwen FE, Van't Veer LJ, Southey MC, Hopper JL, Apicella C, Haiman CA, Henderson BE, Le Marchand L, Kolonel LN, Kristensen V, Grenaker Alnaes G, Hunter DJ, Kraft P, Cox DG, Hankinson SE, Seynaeve C, Vreeswijk MP, Tollenaar RA, Devilee P, Chanock S, Lissowska J, Brinton L, Peplonska B, Czene K, Hall P, Li Y, Liu J, Balasubramanian S, Rafii S, Reed MW, Pooley KA, Conroy D, Baynes C, Kang D, Yoo KY, Noh DY, Ahn SH, Shen CY, Wang HC, Yu JC, Wu PE, Anton-Culver H, Ziogoas A, Egan K, Newcomb P, Titus-Ernstoff L, Trentham Dietz A, Sigurdson AJ, Alexander BH, Bhatti P, Allen-Brady K, Cannon-Albright LA, Wong J, , Chenevix-Trench G, Spurdle AB, Beesley J, Pharoah PD, Easton DF, Garcia-Closas M,
Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium.
Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1610-6
Gerestein CG, Eijkemans MJ, de Jong D, van der Burg ME, Dykgraaf RH, Kooi GS, Baalbergen A, Burger CW, Ansink AC
The prediction of progression-free and overall survival in women with an advanced stage of epithelial ovarian carcinoma.
BJOG. 2009 Feb;116(3):372-80
Ghodgaonkar MM, Shah RG, Kandan-Kulangara F, Affar EB, Qi HH, Wiemer E, Shah GM
Abrogation of DNA vector-based RNAi during apoptosis in mammalian cells due to caspase-mediated cleavage and inactivation of Dicer-1.
Cell Death Differ. 2009 Jun;16(6):858-68
Hamberg P, Verweij J
Phase I drug combination trial design: walking the tightrope.
J Clin Oncol. 2009 Sep 20;27(27):4441-3
Hartmann O, Spyratos F, Harbeck N, Dietrich D, Fassbender A, Schmitt M, Eppenberger-Castori S, Vuaroqueaux V, Lerebours F, Welzel K, Maier S, Plum A, Niemann S, Foekens JA, Lesche R, Martens JW
DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy.
Clin Cancer Res. 2009 Jan 1;15(1):315-23
Hirst JE, Gard GB, McIllroy K, Nevell D, Field M
High rates of occult fallopian tube cancer diagnosed at prophylactic bilateral salpingo-oophorectomy.
Int J Gynecol Cancer. 2009 Jul;19(5):826-9
Hollestelle A, Schutte M
Comment Re: MDA-MB-435 and M14 cell lines: identical but not M14 Melanoma?
Cancer Res. 2009 Oct 1;69(19):7893
Hsieh SM, Look MP, Sieuwerts AM, Foekens JA, Hunter KW
Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study.
Breast Cancer Res. 2009;11(5):R75
Jager A, Verweij J, Sleijfer S
Chemotherapy: Adjuvant chemotherapy in older patients with breast cancer.
Nat Rev Clin Oncol. 2009 Oct;6(10):563-5
Jansen MP, Ruigrok-Ritstier K, Dorssers LC, van Staveren IL, Look MP, Meijer-van Gelder ME, Sieuwerts AM, Helleman J, Sleijfer S, Klijn JG, Foekens JA, Berns EM
Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Breast Cancer Res Treat. 2009 Jul;116(2):263-71
Johnatty SE, Couch FJ, Fredericksen Z, Tarrell R, Spurdle AB, Beesley J, Chen X, , , , Gschwantler-Kaulich D, Singer CF, Fuerhauser C, Fink-Retter A, Domchek SM, Nathanson KL, Pankratz VS, Lindor NM, Godwin AK, Caligo MA, Hopper J, Southey MC, Giles GG, Justenhoven C, Brauch H, Hamann U, Ko YD, Heikkinen T, Aaltonen K, Aittomäki K, Blomqvist C, Nevanlinna H, Hall P, Czene K, Liu J, Peock S, Cook M, Platte R, Gareth Evans D, Lalloo F, Eeles R, Pichert G, Eccles D, Davidson R, Cole T, Cook J, Douglas F, Chu C, Hodgson S, Paterson J, Hogervorst FB, Rookus MA, Seynaeve C, Wijnen J, Vreeswijk M, Ligtenberg M, van der Luijt RB, van Os TA, Gille HJ, Blok MJ, , Issacs C, Humphreys MK, McGuffog L, Healey S, Sinilnikova O, Antoniou AC, Easton DF, Chenevix-Trench G,
No evidence that GATA3 rs570613 SNP modifies breast cancer risk.
Breast Cancer Res Treat. 2009 Sep;117(2):371-9
Kappers MH, van Esch JH, Sleijfer S, Danser AH, van den Meiracker AH
Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
J Hypertens. 2009 Dec;27(12):2297-309
Kitzen JJ, de Jonge MJ, Lamers CH, Eskens FA, van der Biessen D, van Doorn L, Ter Steeg J, Brandely M, Puozzo Ch, Verweij J
Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours.
Eur J Cancer. 2009 Jul;45(10):1764-72
Kok M, Linn SC, Van Laar RK, Jansen MP, van den Berg TM, Delahaye LJ, Glas AM, Peterse JL, Hauptmann M, Foekens JA, Klijn JG, Wessels LF, Van't Veer LJ, Berns EM
Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
Breast Cancer Res Treat. 2009 Jan;113(2):275-83
Konings IR, Engels FK, Sleijfer S, Verweij J, Wiemer EA, Loos WJ
Application of prolonged microdialysis sampling in carboplatin-treated cancer patients.
Cancer Chemother Pharmacol. 2009 Aug;64(3):509-16
Konings IR, Verweij J, Wiemer EA, Sleijfer S
The applicability of mTOR inhibition in solid tumors.
Curr Cancer Drug Targets. 2009 May;9(3):439-50
Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten DS, Bartelink H, van de Vijver MJ
Local recurrence after breast-conserving therapy in relation to gene expression patterns in a large series of patients.
Clin Cancer Res. 2009 Jun 15;15(12):4181-90
Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den Ouweland A, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG
Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers.
J Clin Oncol. 2009 Aug 10;27(23):3764-71
Kuijper A, Snijders AM, Berns EM, Kuenen-Boumeester V, van der Wall E, Albertson DG, van Diest PJ
Genomic profiling by array comparative genomic hybridization reveals novel DNA copy number changes in breast phyllodes tumours.
Cell Oncol. 2009;31(1):31-9
Kuijper TM, Ruigrok-Ritstier K, Verhoef-Post M, Piersma D, Bruysters MW, Berns EM, Themmen AP
LH receptor gene expression is essentially absent in breast tumor tissue: implications for treatment.
Mol Cell Endocrinol. 2009 Apr 10;302(1):58-64
Lamers CH, Willemsen RA, van Elzakker PM, Gratama JW, Debets R
Gibbon ape leukemia virus poorly replicates in primary human T lymphocytes: implications for safety testing of primary human T lymphocytes transduced with GALV-pseudotyped vectors.
J Immunother. 2009 Apr;32(3):272-9
Le Cesne A, Van Glabbeke M, Verweij J, Casali PG, Findlay M, Reichardt P, Issels R, Judson I, Schoffski P, Leyvraz S, Bui B, Hogendoorn PC, Sciot R, Blay JY
Absence of progression as assessed by response evaluation criteria in solid tumors predicts survival in advanced GI stromal tumors treated with imatinib mesylate: the intergroup EORTC-ISG-AGITG phase III trial.
J Clin Oncol. 2009 Aug 20;27(24):3969-74
Mann GB, Kang YC, Brand C, Ebeling PR, Miller JA
Secondary causes of low bone mass in patients with breast cancer: a need for greater vigilance.
J Clin Oncol. 2009 Aug 1;27(22):3605-10
Martens JW, Margossian AL, Schmitt M, Foekens J, Harbeck N
DNA methylation as a biomarker in breast cancer.
Future Oncol. 2009 Oct;5(8):1245-56
Mathijssen RH, Gurney H
Irinogenetics: how many stars are there in the sky?
J Clin Oncol. 2009 Jun 1;27(16):2578-9
Mathijssen RH, Sparreboom A
Influence of lean body weight on anticancer drug clearance.
Clin Pharmacol Ther. 2009 Jan;85(1):23; author reply 24
Meijer D, Jansen MP, Look MP, Ruigrok-Ritstier K, van Staveren IL, Sieuwerts AM, van Agthoven T, Foekens JA, Dorssers LC, Berns EM
TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Breast Cancer Res Treat. 2009 Jan;113(2):253-60
Meulenbeld HJ, Hamberg P, de Wit R
Chemotherapy in patients with castration-resistant prostate cancer.
Eur J Cancer. 2009 Sep;45 Suppl 1:161-71
Milne RL, Benítez J, Nevanlinna H, Heikkinen T, Aittomäki K, Blomqvist C, Arias JI, Zamora MP, Burwinkel B, Bartram CR, Meindl A, Schmutzler RK, Cox A, Brock I, Elliott G, Reed MW, Southey MC, Smith L, Spurdle AB, Hopper JL, Couch FJ, Olson JE, Wang X, Fredericksen Z, Schürmann P, Bremer M, Hillemanns P, Dörk T, Devilee P, van Asperen CJ, Tollenaar RA, Seynaeve C, Hall P, Czene K, Liu J, Li Y, Ahmed S, Dunning AM, Maranian M, Pharoah PD, Chenevix-Trench G, Beesley J, , , Bogdanova NV, Antonenkova NN, Zalutsky IV, Anton-Culver H, Ziogas A, Brauch H, Justenhoven C, Ko YD, Haas S, Fasching PA, Strick R, Ekici AB, Beckmann MW, Giles GG, Severi G, Baglietto L, English DR, Fletcher O, Johnson N, dos Santos Silva I, Peto J, Turnbull C, Hines S, Renwick A, Rahman N, Nordestgaard BG, Bojesen SE, Flyger H, Kang D, Yoo KY, Noh DY, Mannermaa A, Kataja V, Kosma VM, García-Closas M, Chanock S, Lissowska J, Brinton LA, Chang-Claude J, Wang-Gohrke S, Shen CY, Wang HC, Yu JC, Chen ST, Bermisheva M, Nikolaeva T, Khusnutdinova E, Humphreys MK, Morrison J, Platte R, Easton DF,
Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.
J Natl Cancer Inst. 2009 Jul 15;101(14):1012-8
Mom CH, Verweij J, Oldenhuis CN, Gietema JA, Fox NL, Miceli R, Eskens FA, Loos WJ, de Vries EG, Sleijfer S
Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.
Clin Cancer Res. 2009 Sep 1;15(17):5584-90
Mostert B, Sleijfer S, Foekens JA, Gratama JW
Circulating tumor cells (CTCs): detection methods and their clinical relevance in breast cancer.
Cancer Treat Rev. 2009 Aug;35(5):463-74
Ng SS, Mahmoudi T, Danenberg E, Bejaoui I, de Lau W, Korswagen HC, Schutte M, Clevers H
Phosphatidylinositol 3-kinase signaling does not activate the wnt cascade.
J Biol Chem. 2009 Dec 18;284(51):35308-13
Oldenmenger WH, Sillevis Smitt PA, van Dooren S, Stoter G, van der Rijt CC
A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal.
Eur J Cancer. 2009 May;45(8):1370-80
Oosten AW, Seynaeve C, Schmitz PI, den Bakker MA, Verweij J, Sleijfer S
Outcomes of first-line chemotherapy in patients with advanced or metastatic leiomyosarcoma of uterine and non-uterine origin.
Sarcoma. 2009;2009:348910
Pothof J, Verkaik NS, van IJcken W, Wiemer EA, Ta VT, van der Horst GT, Jaspers NG, van Gent DC, Hoeijmakers JH, Persengiev SP
MicroRNA-mediated gene silencing modulates the UV-induced DNA-damage response.
EMBO J. 2009 Jul 22;28(14):2090-9
Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, Tredan O, Verweij J, Biron P, Labidi I, Guastalla JP, Bachelot T, Perol D, Chabaud S, Hogendoorn PC, Cassier P, Dufresne A, Blay JY,
Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas.
Cancer Res. 2009 Jul 1;69(13):5383-91
Riaz M, Elstrodt F, Hollestelle A, Dehghan A, Klijn JG, Schutte M
Low-risk susceptibility alleles in 40 human breast cancer cell lines.
BMC Cancer. 2009 Jul 16;9(1):236
Romeo S, Debiec-Rychter M, Van Glabbeke M, Van Paassen H, Comite P, Van Eijk R, Oosting J, Verweij J, Terrier P, Schneider U, Sciot R, Blay JY, Hogendoorn PC,
Cell cycle/apoptosis molecule expression correlates with imatinib response in patients with advanced gastrointestinal stromal tumors.
Clin Cancer Res. 2009 Jun 15;15(12):4191-8
Schilder CM, Eggens PC, Seynaeve C, Linn SC, Boogerd W, Gundy CM, Beex LV, Van Dam FS, Schagen SB
Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study.
Acta Oncol. 2009;48(1):76-85
Schmitt M, Foekens JA
Circulating tumor cells in blood of primary breast cancer patients assessed by a novel RT-PCR test kit and comparison with status of bone marrow-disseminated tumor cells.
Breast Cancer Res. 2009;11(5):109
Schrohl AS, Look MP, Meijer-van Gelder ME, Foekens JA, Brünner N
Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer patients: A retrospective study.
BMC Cancer. 2009;9:322
Sieuwerts AM, Kraan J, Bolt-de Vries J, van der Spoel P, Mostert B, Martens JW, Gratama JW, Sleijfer S, Foekens JA
Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR.
Breast Cancer Res Treat. 2009 Dec;118(3):455-68
Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA
Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells.
J Natl Cancer Inst. 2009 Jan 7;101(1):61-6
Sleijfer S
Management of aggressive fibromatosis: can we unravel the maze of treatment options?
Eur J Cancer. 2009 Nov;45(17):2928-9
Sleijfer S, Ray-Coquard I, Papai Z, Le Cesne A, Scurr M, Schöffski P, Collin F, Pandite L, Marreaud S, De Brauwer A, van Glabbeke M, Verweij J, Blay JY
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).
J Clin Oncol. 2009 Jul 1;27(19):3126-32
Sleijfer S, Verweij J
The price of success: cost-effectiveness of molecularly targeted agents.
Clin Pharmacol Ther. 2009 Feb;85(2):136-8
Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, Martens JW
Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group.
Eur J Cancer. 2009 Jan;45(1):74-81
Sparreboom A, Verweij J
Advances in cancer therapeutics.
Clin Pharmacol Ther. 2009 Feb;85(2):113-7
Steeghs N, Eskens FA, Gelderblom H, Verweij J, Nortier JW, Ouwerkerk J, van Noort C, Mariani M, Spinelli R, Carpinelli P, Laffranchi B, de Jonge MJ
Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors.
J Clin Oncol. 2009 Oct 20;27(30):5094-101
Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT, Stebbings LA, Leroy C, Edkins S, Mudie LJ, Greenman CD, Jia M, Latimer C, Teague JW, Lau KW, Burton J, Quail MA, Swerdlow H, Churcher C, Natrajan R, Sieuwerts AM, Martens JW, Silver DP, Langerød A, Russnes HE, Foekens JA, Reis-Filho JS, van 't Veer L, Richardson AL, Børresen-Dale AL, Campbell PJ, Futreal PA, Stratton MR
Complex landscapes of somatic rearrangement in human breast cancer genomes.
Nature. 2009 Dec 24;462(7276):1005-10
Strijbos MH, Kraan J, Lamers CH, Sleijfer S, Gratama JW
Quantification of circulating endothelial cells by flow cytometry.
Clin Cancer Res. 2009 May 15;15(10):3640; author reply 3640-1
Strijbos MH, Landburg PP, Nur E, Teerlink T, Leebeek FW, Rijneveld AW, Biemond BJ, Sleijfer S, Gratama JW, Duits AJ, Schnog JJ,
Circulating endothelial cells: a potential parameter of organ damage in sickle cell anemia?
Blood Cells Mol Dis. 2009 Jul-Aug;43(1):63-7
Strijbos MH, Verhoef C, Gratama JW, Sleijfer S
On the origin of (CD105+) circulating endothelial cells.
Thromb Haemost. 2009 Aug;102(2):347-51
Swaak-Kragten AT, de Wilt JH, Schmitz PI, Bontenbal M, Levendag PC
Multimodality treatment for anaplastic thyroid carcinoma--treatment outcome in 75 patients.
Radiother Oncol. 2009 Jul;92(1):100-4
Tan MB, Bleiker EM, Menke-Pluymers MB, Van Gool AR, van Dooren S, Van Geel BN, Tilanus-Linthorst MM, Bartels KC, Klijn JG, Brekelmans CT, Seynaeve C
Standard psychological consultations and follow up for women at increased risk of hereditary breast cancer considering prophylactic mastectomy.
Hered Cancer Clin Pract. 2009;7(1):6
Toussaint J, Sieuwerts AM, Haibe-Kains B, Desmedt C, Rouas G, Harris AL, Larsimont D, Piccart M, Foekens JA, Durbecq V, Sotiriou C
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.
BMC Genomics. 2009;10:424
Troost MM, Sternberg CN, de Wit R
Management of good risk germ-cell tumours.
BJU Int. 2009 Nov;104(9 Pt B):1387-91
Umar A, Kang H, Timmermans AM, Look MP, Meijer-van Gelder ME, den Bakker MA, Jaitly N, Martens JW, Luider TM, Foekens JA, Pasa-Tolić L
Identification of a putative protein profile associated with tamoxifen therapy resistance in breast cancer.
Mol Cell Proteomics. 2009 Jun;8(6):1278-94
van Agthoven T, Sieuwerts AM, Meijer-van Gelder ME, Look MP, Smid M, Veldscholte J, Sleijfer S, Foekens JA, Dorssers LC
Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance.
J Clin Oncol. 2009 Feb 1;27(4):542-9
van Agthoven T, Sieuwerts AM, Veldscholte J, Meijer-van Gelder ME, Smid M, Brinkman A, den Dekker AT, Leroy IM, van Ijcken WF, Sleijfer S, Foekens JA, Dorssers LC
CITED2 and NCOR2 in anti-oestrogen resistance and progression of breast cancer.
Br J Cancer. 2009 Dec 1;101(11):1824-32
van Alphen RJ, Wiemer EA, Burger H, Eskens FA
The spliceosome as target for anticancer treatment.
Br J Cancer. 2009 Jan 27;100(2):228-32
van den Belt-Dusebout AW, Aleman BM, Besseling G, de Bruin ML, Hauptmann M, van 't Veer MB, de Wit R, Ribot JG, Noordijk EM, Kerst JM, Gietema JA, van Leeuwen FE
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy.
Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1420-9
van Dooren S, Duivenvoorden HJ, Passchier J, Bannink M, Tan MB, Oldenmenger WH, Seynaeve C, van der Rijt CC
The Distress Thermometer assessed in women at risk of developing hereditary breast cancer.
Psychooncology. 2009 Oct;18(10):1080-7
van Dooren S, van Veluw HT, van Zuylen L, Rietjens JA, Passchier J, van der Rijt CC
Exploration of concerns of relatives during continuous palliative sedation of their family members with cancer.
J Pain Symptom Manage. 2009 Sep;38(3):452-9
van Erp NP, Eechoute K, van der Veldt AA, Haanen JB, Reyners AK, Mathijssen RH, Boven E, van der Straaten T, Baak-Pablo RF, Wessels JA, Guchelaar HJ, Gelderblom H
Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.
J Clin Oncol. 2009 Sep 10;27(26):4406-12
van Lindert NH, Bienfait HP, Gratama JW, Vriesema H, Ten Hove W, Vermeulen EG, van Leeuwen RB
Screening for aneurysm of the abdominal aorta: prevalence in patients with stroke or TIA.
Eur J Neurol. 2009 May;16(5):602-7
van Meerten E, van der Gaast A, Tilanus HW, Poley JW, Muller K, van Dekken H
Pathological analysis after neoadjuvant chemoradiotherapy for esophageal carcinoma: the Rotterdam experience.
J Surg Oncol. 2009 Jul 1;100(1):32-7
van Weerden WM, Bangma C, de Wit R
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.
Br J Cancer. 2009 Jan 13;100(1):13-8
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC
Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview.
Int J Gynecol Cancer. 2009 Apr;19(3):431-46
van Wijk FH, van der Burg ME, Burger CW, Vergote I, van Doorn HC
Management of surgical stage III and IV endometrioid endometrial carcinoma: an overview.
Int J Gynecol Cancer. 2009 Apr;19(3):431-46
Verschuur EM, Steyerberg EW, Tilanus HW, Polinder S, Essink-Bot ML, Tran KT, van der Gaast A, Stassen LP, Kuipers EJ, Siersema PD
Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial.
Br J Cancer. 2009 Jan 13;100(1):70-6
Verweij J
Soft tissue sarcoma trials: one size no longer fits all.
J Clin Oncol. 2009 Jul 1;27(19):3085-7
Verweij J, Therasse P, Eisenhauer E,
Cancer clinical trial outcomes: any progress in tumour-size assessment?
Eur J Cancer. 2009 Jan;45(2):225-7
Wasielewski M, den Bakker MA, van den Ouweland A, Meijer-van Gelder ME, Portengen H, Klijn JG, Meijers-Heijboer H, Foekens JA, Schutte M
CHEK2 1100delC and male breast cancer in the Netherlands.
Breast Cancer Res Treat. 2009 Jul;116(2):397-400
Wasielewski M, Hanifi-Moghaddam P, Hollestelle A, Merajver SD, van den Ouweland A, Klijn JG, Ethier SP, Schutte M
Deleterious CHEK2 1100delC and L303X mutants identified among 38 human breast cancer cell lines.
Breast Cancer Res Treat. 2009 Jan;113(2):285-91
Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA, Massagué J
Latent bone metastasis in breast cancer tied to Src-dependent survival signals.
Cancer Cell. 2009 Jul 7;16(1):67-78
Zhang Y, Martens JW, Yu JX, Jiang J, Sieuwerts AM, Smid M, Klijn JG, Wang Y, Foekens JA
Copy number alterations that predict metastatic capability of human breast cancer.
Cancer Res. 2009 May 1;69(9):3795-801
Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA
The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy.
Breast Cancer Res Treat. 2009 Jul;116(2):303-9